Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
Zorguitgaven kanker stijgen vooral door nieuwe behandelingen
mrt 2025 | Dermato-oncologie, Leukemie, Longoncologie, MM